- Home
- EDN vs LQDA Comparison
EDN vs LQDA Comparison
Compare EDN & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDN
- LQDA
- Stock Information
- Founded
- EDN 1992
- LQDA 2004
- Country
- EDN Argentina
- LQDA United States
- Employees
- EDN N/A
- LQDA N/A
- Industry
- EDN Electric Utilities: Central
- LQDA Biotechnology: Pharmaceutical Preparations
- Sector
- EDN Utilities
- LQDA Health Care
- Exchange
- EDN Nasdaq
- LQDA Nasdaq
- Market Cap
- EDN 1.3B
- LQDA 1.3B
- IPO Year
- EDN 2007
- LQDA 2018
- Fundamental
- Price
- EDN $34.06
- LQDA $15.57
- Analyst Decision
- EDN
- LQDA Strong Buy
- Analyst Count
- EDN 0
- LQDA 7
- Target Price
- EDN N/A
- LQDA $28.33
- AVG Volume (30 Days)
- EDN 108.2K
- LQDA 1.0M
- Earning Date
- EDN 03-11-2025
- LQDA 03-19-2025
- Dividend Yield
- EDN N/A
- LQDA N/A
- EPS Growth
- EDN 42.19
- LQDA N/A
- EPS
- EDN 0.30
- LQDA N/A
- Revenue
- EDN $1,981,694,257.00
- LQDA $13,996,000.00
- Revenue This Year
- EDN $51.74
- LQDA $256.78
- Revenue Next Year
- EDN N/A
- LQDA $222.00
- P/E Ratio
- EDN $6.66
- LQDA N/A
- Revenue Growth
- EDN 33.82
- LQDA N/A
- 52 Week Low
- EDN $13.78
- LQDA $8.26
- 52 Week High
- EDN $51.69
- LQDA $16.81
- Technical
- Relative Strength Index (RSI)
- EDN 46.50
- LQDA 58.18
- Support Level
- EDN $31.20
- LQDA $14.04
- Resistance Level
- EDN $34.78
- LQDA $14.61
- Average True Range (ATR)
- EDN 2.02
- LQDA 0.69
- MACD
- EDN 0.19
- LQDA 0.06
- Stochastic Oscillator
- EDN 49.25
- LQDA 92.11
About EDN Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)
Empresa Distribuidora y Comercializadora Norte SA is engaged in the distribution and sale of electricity. The firm's concession area covers the northern portion of the city of Buenos Aires mainly to residential, commercial, industrial, and public service.
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.